L.I. MALTSEVA, YU.V. GARIFULLOVA

 Kazan State Medical Academy — Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan

Contact details:

Maltseva L.I. — MD, Professor of the Department of Obstetrics and Gynecology

Address: 36 Butlerov St., 420012 Kazan, Russian Federation, tel.: +7 (843) 236-46-41, e-mail: laramalc@mail.ru

The authors analyzed data from foreign and Russian articles published over the past 10 years on the problems of hormonal balance in women with benign breast diseases (BBD), among which benign dysplasia is a proven independent risk factor for breast cancer (BC). The most important links in the pathogenesis of proliferative breast lesions in women of reproductive age include hormonal factors such as hyperestrogenism, hyperprolactinemia, insulin resistance, and vitamin D deficiency. Recent studies demonstrate the possibility of other hormonal systems — mineralcorticoid, glucocorticoid and androgen receptors in the development and progression of proliferative conditions in mammary glands. Assessing hormonal imbalance in women with breast pathology may be one of the key points in personalized prevention and treatment of breast cancer.

Key words: benign breast diseases, risk factors, breast cancer, sex hormones, prolactin, vitamin D.

REFERENCES

1. Kolak A., Kamińska M., Sygit K. et al. Primary and secondary prevention of breast cancer. Ann. Agric. Environ. Med, 2017, vol. 24 (4), pp. 549–553. DOI: 10.26444/aaem/75943
2. O’Driscoll J., Burton A., Maskarinec G. et al. Reproductive factors and mammographic density within the International Consortium of Mammographic Density: A cross-sectional study. Breast Cancer Res, 2024, vol. 26 (1), pp. 139. DOI: 10.1186/s13058-024-01890-x
3. Engin A. Obesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation. Adv. Exp. Med. Biol, 2024, vol. 1460, pp. 767–819. DOI: 10.1007/978-3-031-63657-8_26
4. NAMS POSITION STATEMENT The 2022 hormone therapy position statement of The North American Menopause Society Menopause. J. North Am. Menopause Soc, 2022, vol. 29 (7), pp. 767–794.
5. Fournier A., Berrino F., Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008, Jan; 107(1):103-11. doi: 10.1007/s10549-007-9523-x.
6. Yuk J.S. Relationship between menopausal hormone therapy and breast cancer: A nationwide population-based cohort study. Int. J. Gynaecol. Obstet, 2024, vol. 166 (2), pp. 735–744. DOI: 10.1002/ijgo.15461
7. EBCC 2022: Women with benign breast disease face higher risk of breast cancer in the long term. 18 Nov 2022.
8. Manna E.D.F., Serrano D., Aurilio G. et al. Chemoprevention and Lifestyle Modifications for Risk Reduction in Sporadic and Hereditary Breast Cancer. Healthcare (Basel), 2023, vol. 11 (16), p. 2360. DOI: 10.3390/healthcare11162360
9. Keyzer-Dekker C.M., van Esch L., Schreurs W.H. et al. Health care utilization one year following the diagnosis benign breast disease or breast cancer. Breast, 2012, vol. 21 (6), pp. 746–750.
10. Experts share new recommendations for managing benign breast lesions, available at: https://radiologybusiness.com/topics/medical-imaging/womens-imaging/experts-share-new-recommendations-managing-benign-breast-lesions
11. Lisanti M.R, Tsirigos A., Pavlides S. et al. JNK1 stress signaling is hyper-activated in high breast density andthe tumor stroma: connecting fibrosis, inflammation. and sternness for cancer prevention. Cell Cycle, 2014, vol. 13 (4), pp. 580–599. DOI: 10.4161/cc.27379
12. Ashrafyan L.A., Kiselev V.I., Muyzhnek E.L. Patogeneticheskaya profilaktika raka reproduktivnykh organov [Pathogenetic prevention of reproductive organ cancer]. Moscow: Izd. Dimitreyd Grafik Grupp, 2009. 171 p.
13. Kogan I.Yu. Mastopathy: new approaches to diagnostics and pathogenetic therapy. Zhurnal akusherstva i zhenskikh bolezney, 2010, vol. LIX, iss. 1, pp. 66–70 (in Russ.).
14. Podzolkova N.M., Sumyatina L.V., Mokhova Yu.A. Prolactin and mammary glands. New data from randomized trials. Akusherstvo i ginekologiya, 2015, no. 12, pp. 46–50 (in Russ.).
15. Wassan Nori, Muna Abdul Ghani Zghair, Shaymaa Khalid Abdulqader, Reia Jaber Mastalgia in Fibrocystic Changes; From the Diagnosis Bench to Innovative Therapy: A Narrative. Open Med. Chem. J, 2025. DOI: 10.2174/0118741045371715250404073206
16. Chung-Che Tsai, Yung-Ning Yang, Kuan Wang et al. Progesterone modulates cell growth via integrin αvβ3-dependent pathway in progesterone receptor-negative MDA-MB-231 cells. Heliyon, 2024, vol. 10 (13), pp. e34006. DOI: 10.1016/j.heliyon.2024.e34006
17. Kim J., Munster P.N. Estrogens and breast cancer. Ann. Oncol, 2025, vol. 36 (2), pp. 134–148.
18. Zhirnova A.S., Shevlyuk N.N., Kurlayev P.P. Morphological features of mammary gland tissue in women of different age groups under normal conditions and with mastopathy. Zhurnal anatomii i gistopatologii, 2015, vol. 4, no. 4, pp. 34–38 (in Russ.).
19. Qian Pu, Peng Li, Minghui Su, Dezong Gao. Analysis of the clinicopathological and imaging features in breast intraductal papillary lesions with or without pathological nipple discharge. Sci. Rep, 2025, vol. 15. Art. 2478.
20. Brinton L.A., Vessey M.P., Flavel R., Yeates D. Risk factors for benign breast disease. Am. J. Epidemiol, 1981, vol. 113 (3), pp. 203–214. DOI: 10.1093/oxfordjournals.aje.a113089
21. Adolf E. Schindler Non-Contraceptive Benefits of Oral Hormonal Contraceptives. Int. J. Endocrinol. Metab, 2012, vol. 11 (1), pp. 41–47. DOI: 10.5812/ijem.4158
22. Charreau I., Plu-Bureau G., Bachelot A. et al. Oral contraceptive use and risk of benign breast disease in a French case-control study of young women. Eur. J. Cancer Prev, 1993, vol. 2 (2), pp. 147–154.
23. Royal College of General Practitioners’ Oral Contraception Study. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet, 1977, vol. 1 (8012), p. 624.
24. Navarrete M.A., Maier C.M., Falzoni R. et al. Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res, 2005, vol. 7 (3), pp. R306–313.
25. Linda A. Schuler, Kathleen A. Oleary. Prolactin: The Third Hormone in Breast Cancer. Front. Endocrinol. (Lausanne), 2022, vol. 13. 910978.
26. Gutzman J.H., Miller K.K., Schuler L.A. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J. Steroid. Biochem. Mol. Biol, 2004, vol. 88 (1), pp. 69–77. DOI: 10.1016/j.jsbmb.2003.10.008
27. Al-Hajj M., Wicha M.S., Benito-Hernandez A. et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA, 2003, vol. 100, pp. 3983–3988.
28. Melikhova V.S. Creation of functional breast tissue from a single stem cell. Geny i kletki, 2006, vol. 1, no. 1, pp. 21–22 (in Russ.).
29. Tsuchiya H., Shiota G. Immune evasion by cancer stem cells. Regen Ther, 2021, vol. 17, pp. 20–33. DOI: 10.1016/j.reth.2021.02.006
30. Hammer A., Diakonova M. Prolactin-induced tyrosyl phosphorylation of PAK1 facilitates epithelial-mesenchymal transition. Micro Publ. Biol, 2024, vol. 2024. DOI: 10.17912/micropub.biology.001136.
31. Szukiewicz D. Current Insights in Prolactin Signaling and Ovulatory Function. Int. J. Mol. Sci, 2024, vol. 25 (4), p. 1976.
32. Sharles V. Cleveger, Hallgeir Rui. Breast Cancer and Prolactin — New Mechanisms and Models. Rev. Endocrinol, 2022, vol. 163 (10).
33. Strader A.D., Buntin J.D. Changes in agouti-related peptide during the ring dove breeding cycle in relation to prolactin and parental hyperphagia. J. Neuroendocrinol, 2003, vol. 15 (11), pp. 1046–1053. DOI: 10.1046/j.1365-2826.2003.01092
34. Mariano L., Nicosia L., Scolari S. et al. Diabetic Mastopathy: A Monocentric Study to Explore This Uncommon Breast Disease. Diagnostics (Basel), 2024, vol. 14 (23), p. 2749.
35. Sahin S., Erdem G.U., Karatas F. The association between body mass index and immunohistochemical subtypes in breast cancer. Breast, 2017, vol. 32, pp. 227–236. DOI: 10.1016/j.breast.2016.09.019
36. Musina E.V., Kogan I.Yu. Possibilities of using biguanides in fibrocystic disease in women of reproductive age. Arkhiv, 2019, vol. 68, no. 3, pp. 35–40 (in Russ.). DOI: 10.17816/JOWD68335-40
37. Horne H.N., Sherman M.E., Pfeiffer R.M. et al. Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. Breast Cancer Res, 2016, vol. 18 (1), p. 24. DOI: 10.1186/s13058-016-0678-4
38. Garland C.F., Gorham E.D., Mohr S.B. et al. Vitamin D and prevention of breast cancer: Pooled analysis. J. Steroid Biochem. Mol. Biol, 2007, vol. 103, pp. 708–711.
39. Garland C.F., Gorham E.D., Mohr S.B. et al. Vitamin D for Cancer Prevention: Global Perspective. Ann. Epidemiol, 2009, vol. 19, pp. 468–483.
40. Lopes N., Sousa B., Martins D. et al. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer, 2010, vol. 10, p. 483. DOI: 10.1186/1471-2407-10-483
41. Niu D., Li C., Yan X. et al. The relationship between antidepressants and breast cancer: evidence from Mendelian randomization. Cancer Causes Control, 2024, vol. 35 (1), pp. 55–62. DOI: 10.1007/s10552-023-01766-z
42. Mal′tseva L.I., Garifullova Yu.V., Kalinkina M.G. The Role of Vitamin D in Reducing Breast Density in Women with Diffuse Mastopathy. Akusherstvo i ginekologiya. Prakticheskaya meditsina, 2018, vol. 16, no. 6 (18) (in Russ.).
43. Garifullova Yu.V. Features of the Hormonal Status of Patients with Benign Breast Diseases and Various Types of Gynecological Pathology. Akusherstvo i ginekologiya. Prakticheskaya meditsina, 2018, vol. 16, no. 6 (18) (in Russ.).
44. Mingzhen Cai, Keely McNamara, Yuto Yamazaki. The role of mineralocorticoids and glucocorticoids under the impact of 11β hydroxysteroid dehydrogenase in human breast lesions. Med. Mol. Morphol, 2022, vol. 55, pp. 110–122.
45. Vidović V., Davidov I., Ružić Z. et al. Androgen Receptors in Human Breast Cancer and Female Canine Mammary Tumors. Molecules, 2025, vol. 30 (7), p. 1411. DOI: 10.3390/molecules30071411
46. Zhu Q., Bennett D., Hagemann I.S. et al. Ultrasound-guided diffuse optical tomography: an adjunct to ultrasound that can reduce unnecessary breast biopsies. Breast Cancer Res, 2025, vol. 28 (1), p. 31. DOI: 10.1186/s13058-025-02206-3
47. Li J., Zhao B., Chen Y. et al. Research on the establishment of a four-classification model for breast mass ultrasound images based on transfer learning. PLoS One, 2026, vol. 21 (1), p. e0340111. DOI: 10.1371/journal.pone.0340111